{"id":228,"date":"2026-04-10T23:05:52","date_gmt":"2026-04-11T06:05:52","guid":{"rendered":"https:\/\/taurusmeds.com\/articles\/trt-prostate-cancer-active-surveillance\/"},"modified":"2026-04-10T23:05:55","modified_gmt":"2026-04-11T06:05:55","slug":"trt-prostate-cancer-active-surveillance","status":"publish","type":"post","link":"https:\/\/taurusmeds.com\/articles\/trt-prostate-cancer-active-surveillance\/","title":{"rendered":"TRT for Hypogonadal Men on Prostate Cancer Surveillance What Trials Show"},"content":{"rendered":"<style>\n  a { color: #F1471D !important; }\n  .section-spacing { margin-top: 2rem !important; margin-bottom: 2rem !important; }\n  .toc-list ol { margin-left: 1.25rem !important; }\n<\/style>\n<h2 class=\"wp-block-heading\" id=\"h-title\">TRT for Hypogonadal Men on Prostate Cancer Surveillance: What Trials Show<\/h2>\n<div class=\"wp-block-group section-spacing\">\n<p class=\"wp-block-paragraph\"><strong>Estimated reading time:<\/strong> 11 minutes<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-key-takeaways\">\n<h3 class=\"wp-block-heading\">Key takeaways<\/h3>\n<ul class=\"wp-block-list\">\n<li>Early evidence suggests TRT may be considered for hypogonadal men on active surveillance for low-risk, localized prostate cancer when monitoring is rigorous.<\/li>\n<li>Ongoing Phase IV trials (e.g., NCT07278362) are prospectively tracking disease progression, testosterone restoration, and symptom relief.<\/li>\n<li>Observational data show no significant PSA rise or increase in conversion to active treatment after initiating TRT in carefully selected surveillance patients.<\/li>\n<li>Cardiovascular risk appears neutral in recent large trials, but FDA cautions remain\u2014risk assessment should be individualized.<\/li>\n<li>Findings apply to a narrow population with short-to-intermediate follow-up; long-term oncologic and cardiovascular outcomes remain uncertain.<\/li>\n<\/ul>\n<\/div>\n<div class=\"wp-block-group section-spacing\">\n<h3 class=\"wp-block-heading\">Table of contents<\/h3>\n<nav class=\"toc-list\" aria-label=\"Table of contents\">\n<ol>\n<li><a href=\"#h-intro\">Introduction<\/a><\/li>\n<li><a href=\"#h-why-avoided\">Why TRT Was Historically Avoided in Prostate Cancer<\/a><\/li>\n<li><a href=\"#h-whats-changing\">What\u2019s Changing Now: New Data and Ongoing Trials<\/a><\/li>\n<li><a href=\"#h-nct07278362\">Deep Dive: NCT07278362\u2014The 12-Month Trial<\/a><\/li>\n<li><a href=\"#h-nct06733350\">The Longer View: NCT06733350\u2014Up to 5 Years<\/a><\/li>\n<li><a href=\"#h-observational\">Signals From Observational Studies<\/a><\/li>\n<li><a href=\"#h-cardiovascular\">Cardiovascular Context: Reassurance with Caution<\/a><\/li>\n<li><a href=\"#h-applicability\">Who These Data Apply To\u2014and Who They Don\u2019t<\/a><\/li>\n<li><a href=\"#h-surveillance-protocol\">What Active Surveillance Looks Like When TRT Is Considered<\/a><\/li>\n<li><a href=\"#h-practical-patients\">Practical Implications for Patients<\/a><\/li>\n<li><a href=\"#h-practical-clinicians\">Practical Implications for Clinicians<\/a><\/li>\n<li><a href=\"#h-open-questions\">Open Questions the Trials Aim to Answer<\/a><\/li>\n<li><a href=\"#h-taurus-meds\">How Taurus Meds Fits Into the Conversation<\/a><\/li>\n<li><a href=\"#h-conclusion\">Conclusion<\/a><\/li>\n<\/ol>\n<\/nav>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-intro\">\n<h3 class=\"wp-block-heading\">Introduction<\/h3>\n<p class=\"wp-block-paragraph\">Men with low-risk prostate cancer have historically been told that testosterone replacement therapy (TRT) was off the table. That view is changing. Carefully designed studies now suggest that, in selected hypogonadal men managed with active surveillance, restoring testosterone may not accelerate cancer progression\u2014and may improve quality of life. Two ongoing Phase IV trials are testing this question prospectively, including <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">NCT07278362<\/a>, which follows men for 12 months while assessing safety, testosterone restoration, and symptom relief.<\/p>\n<p class=\"wp-block-paragraph\">This article reviews what the new research is asking, what has been observed so far, and what cautious, informed decision-making looks like for men and clinicians navigating TRT during prostate cancer surveillance.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-why-avoided\">\n<h3 class=\"wp-block-heading\">Why TRT Was Historically Avoided in Prostate Cancer<\/h3>\n<p class=\"wp-block-paragraph\">For decades, the prevailing dogma held that testosterone \u201cfeeds\u201d prostate cancer, based largely on early biological models and case series from the pre-PSA era. This led to a blanket contraindication for TRT in any man with current or prior prostate cancer, regardless of tumor risk or symptoms of hypogonadism.<\/p>\n<p class=\"wp-block-paragraph\">Several developments have prompted a reappraisal:<\/p>\n<ul class=\"wp-block-list\">\n<li>Improved understanding of the androgen receptor saturation model suggests that, beyond a certain point, additional testosterone does not proportionally stimulate cancer growth.<\/li>\n<li>Modern active surveillance protocols (using PSA, MRI, and targeted biopsy) allow closer, safer monitoring of low-risk disease.<\/li>\n<li>Emerging clinical data show stable PSA kinetics and no clear increase in treatment conversion among carefully selected men on surveillance who receive TRT.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">The bottom line: the context has shifted from an absolute \u201cno\u201d to a cautiously monitored \u201cmaybe\u201d for the right patient.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-whats-changing\">\n<h3 class=\"wp-block-heading\">What\u2019s Changing Now: New Data and Ongoing Trials<\/h3>\n<p class=\"wp-block-paragraph\">Recent publications and prospective trials are starting to fill evidence gaps.<\/p>\n<ul class=\"wp-block-list\">\n<li>A 2024 report summarized that available evidence does not support adverse oncologic outcomes from TRT in hypogonadal men on active surveillance for localized prostate cancer, including no signal toward increased conversion to treatment in a matched cohort analysis.<\/li>\n<li>A 2024 review found no significant change in PSA after starting testosterone therapy among men on active surveillance, despite improved testosterone levels.<\/li>\n<li>Two Phase IV studies\u2014<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">NCT07278362<\/a> and <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06733350\" target=\"_blank\" rel=\"noopener\">NCT06733350<\/a>\u2014are prospectively evaluating safety, symptom relief, PSA kinetics, imaging, and biopsy outcomes. These studies are designed to move beyond retrospective series and carefully track how disease behaves under TRT.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Importantly, this evolving evidence applies to low-risk, localized disease under structured surveillance and does not extend to intermediate-unfavorable or high-risk cancers.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-nct07278362\">\n<h3 class=\"wp-block-heading\">Deep Dive: NCT07278362\u2014The 12-Month Trial Many Patients Are Asking About<\/h3>\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">NCT07278362<\/a> is a Phase IV investigation focusing on men with newly diagnosed, low-risk prostate cancer on active surveillance who also have clinical hypogonadism.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Key features of the protocol:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> Hypogonadal men with low-risk localized prostate cancer managed on active surveillance. Higher-risk categories are excluded.<\/li>\n<li><strong>Intervention:<\/strong> Testosterone cypionate 100 mg weekly (as part of the study design; not a clinical recommendation).<\/li>\n<li><strong>Duration:<\/strong> 12 months of treatment and monitoring.<\/li>\n<li><strong>Primary endpoint:<\/strong> Disease progression at 12 months, typically defined as biopsy grade progression or decision to transition from surveillance to active treatment.<\/li>\n<li><strong>Secondary endpoints:<\/strong>\n<ul>\n<li>Restoration of total testosterone to physiological range<\/li>\n<li>Symptom improvement using validated patient-reported measures (e.g., Aging Male Symptoms\/AMS scale)<\/li>\n<li>Prostate cancer safety signals: PSA kinetics, MRI findings, and biopsy outcomes<\/li>\n<li>Routine TRT safety including hematocrit monitoring for erythrocytosis<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\"><em>What this means for patients:<\/em> The trial is designed to answer whether symptom relief and normalized testosterone can be achieved without increasing the short-term risk of cancer progression in a tightly monitored setting.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-nct06733350\">\n<h3 class=\"wp-block-heading\">The Longer View: NCT06733350\u2014Up to 5 Years of Follow-Up<\/h3>\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06733350\" target=\"_blank\" rel=\"noopener\">NCT06733350<\/a> extends observation up to five years and compares three real-world groups:<\/p>\n<ul class=\"wp-block-list\">\n<li>Men with normal testosterone<\/li>\n<li>Hypogonadal men who elect TRT<\/li>\n<li>Hypogonadal men who decline TRT<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\"><strong>Outcomes include:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li>Gleason grade progression<\/li>\n<li>PSA kinetics and MRI changes<\/li>\n<li>Patient-reported outcomes such as IPSS (urinary symptoms) and SHIM (erectile function)<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">This design will help clarify whether TRT is neutral, beneficial, or harmful in terms of oncologic outcomes and how it affects everyday quality of life in this specific setting.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-observational\">\n<h3 class=\"wp-block-heading\">What We\u2019ve Seen So Far: Signals From Observational Studies<\/h3>\n<p class=\"wp-block-paragraph\">While randomized data are limited in this exact population, several early findings are informative:<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Progression and treatment conversion:<\/strong> A 2024 matched cohort analysis reported that TRT was not associated with conversion from surveillance to active treatment in men with localized prostate cancer on active surveillance.<\/li>\n<li><strong>PSA response:<\/strong> A 2024 review found no significant PSA elevation after starting TRT in active-surveillance patients, even as testosterone levels increased.<\/li>\n<li><strong>Quality of life:<\/strong> Across many randomized trials in hypogonadal men (not limited to prostate cancer), TRT reliably improves sexual desire, erectile function, and overall sexual activity. The current trials bring these endpoints into the active surveillance context using validated tools, including AMS.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\"><em>Interpreting these data:<\/em> They are reassuring but not definitive. Most studies are small, observational, and short to intermediate in duration\u2014precisely why the ongoing Phase IV trials matter.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-cardiovascular\">\n<h3 class=\"wp-block-heading\">Cardiovascular Context: Reassurance with Ongoing Caution<\/h3>\n<p class=\"wp-block-paragraph\">TRT\u2019s cardiovascular profile has been debated. The regulatory picture has clarified somewhat:<\/p>\n<ul class=\"wp-block-list\">\n<li>The FDA-mandated TRAVERSE trial reported non-inferiority of AndroGel 1.62% versus placebo for major adverse cardiovascular events, with no new safety signals. This supports cardiovascular neutrality in appropriately selected men.<\/li>\n<li>Nonetheless, FDA labeling continues to include cautions about potential increased risk of myocardial infarction and stroke. Past observational studies have reached mixed conclusions, and trial populations may differ from older men with multiple comorbidities.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">For men with low-risk prostate cancer on surveillance, cardiovascular risk assessment remains individualized. Shared decision-making should integrate age, baseline cardiovascular status, symptom burden, and patient priorities.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-applicability\">\n<h3 class=\"wp-block-heading\">Who These Data Apply To\u2014and Who They Don\u2019t<\/h3>\n<p class=\"wp-block-paragraph\">Current trial designs are intentionally conservative. They typically include:<\/p>\n<ul class=\"wp-block-list\">\n<li>Low-risk, localized prostate cancer (e.g., favorable pathology) on established active surveillance<\/li>\n<li>Confirmed hypogonadism on repeat morning testosterone tests and appropriate clinical symptoms<\/li>\n<li>No features of intermediate-unfavorable, high-risk, or very high-risk disease<\/li>\n<li>Exclusions such as elevated hematocrit at baseline or significant thromboembolic history<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">If you do not fit this profile, the emerging evidence on TRT during prostate cancer surveillance may not apply. If you do, these trials are designed to inform a more nuanced, individualized conversation about risks and benefits.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-surveillance-protocol\">\n<h3 class=\"wp-block-heading\">What Active Surveillance Looks Like When TRT Is Considered<\/h3>\n<p class=\"wp-block-paragraph\">While protocols vary, the shared theme is vigilant monitoring with a low threshold to pause or cease TRT if cancer behavior changes. Components may include:<\/p>\n<ul class=\"wp-block-list\">\n<li>PSA monitoring at regular intervals<\/li>\n<li>MRI as indicated by PSA kinetics or clinical findings<\/li>\n<li>Scheduled or trigger-based biopsies per the surveillance protocol<\/li>\n<li>Routine TRT safety labs (including hematocrit) to watch for erythrocytosis<\/li>\n<li>Symptom tracking with validated scales (e.g., AMS, SHIM), recognizing that symptomatic benefit is a key reason men seek treatment<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Patients should expect frequent communication with their care team and clear exit criteria if evidence of progression appears.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-practical-patients\">\n<h3 class=\"wp-block-heading\">Practical Implications for Patients Considering TRT on Surveillance<\/h3>\n<ul class=\"wp-block-list\">\n<li><strong>Conversations are changing:<\/strong> If you have low-risk localized prostate cancer and well-documented hypogonadism, TRT may be a discussion worth having\u2014not an automatic \u201cno.\u201d<\/li>\n<li><strong>Quality-of-life matters:<\/strong> Addressing fatigue, libido, and sexual function is a legitimate health goal, provided safety is closely managed.<\/li>\n<li><strong>Monitoring is non-negotiable:<\/strong> The trials emphasize structured surveillance. If you\u2019re not comfortable with regular bloodwork, imaging, and potential biopsies, TRT during active surveillance may not be the right path.<\/li>\n<li><strong>Time horizon matters:<\/strong> Current data are strongest for 12 months to several years. Longer-term outcomes (5\u201310+ years) remain uncertain.<\/li>\n<\/ul>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-practical-clinicians\">\n<h3 class=\"wp-block-heading\">Practical Implications for Clinicians<\/h3>\n<ul class=\"wp-block-list\">\n<li><strong>Patient selection is the fulcrum:<\/strong> Low-risk disease, confirmed biochemical hypogonadism with symptoms, and careful review of cardiovascular and hematologic history are essential.<\/li>\n<li><strong>Shared decision-making:<\/strong> Discuss uncertainty (especially long-term oncologic outcomes), potential benefits, and clear stop rules.<\/li>\n<li><strong>Prostate monitoring:<\/strong> Consider a low threshold for MRI and repeat biopsy aligned with your active surveillance protocol.<\/li>\n<li><strong>Documented goals:<\/strong> Define physiologic testosterone restoration targets and symptom metrics up front (e.g., AMS), and reassess systematically.<\/li>\n<\/ul>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-open-questions\">\n<h3 class=\"wp-block-heading\">Open Questions the Trials Aim to Answer<\/h3>\n<ul class=\"wp-block-list\">\n<li>Will safety signals hold beyond 12 months (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">NCT07278362<\/a>) and out to five years (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06733350\" target=\"_blank\" rel=\"noopener\">NCT06733350<\/a>)?<\/li>\n<li>What is the best monitoring cadence\u2014PSA plus MRI annually, or biopsy at fixed intervals?<\/li>\n<li>Do certain PSA or MRI patterns predict who should avoid or discontinue TRT?<\/li>\n<li>How do outcomes differ in older men with multiple comorbidities?<\/li>\n<li>Can findings be extended to favorable-intermediate risk in a future, carefully designed study?<\/li>\n<\/ul>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-taurus-meds\">\n<h3 class=\"wp-block-heading\">How Taurus Meds Fits Into the Conversation<\/h3>\n<p class=\"wp-block-paragraph\">Men exploring TRT with a history of low-risk prostate cancer need coordinated care, consistent access to medications, and reliable lab monitoring. Taurus Meds supports clinicians and patients with:<\/p>\n<ul class=\"wp-block-list\">\n<li>Transparent access pathways for FDA-approved testosterone products<\/li>\n<li>Coordination of routine lab monitoring schedules requested by care teams<\/li>\n<li>Patient education resources aligned with current evidence and safety guidance<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Our goal is to help the right patients receive the right therapy\u2014safely, consistently, and under the guidance of their oncology and urology teams.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-conclusion\">\n<h3 class=\"wp-block-heading\">Conclusion<\/h3>\n<p class=\"wp-block-paragraph\">For a narrowly defined group\u2014hypogonadal men on active surveillance for low-risk localized prostate cancer\u2014the old blanket prohibition on TRT is giving way to a cautious, evidence-informed approach. Early data suggest no clear signal toward accelerated progression, and symptom improvements are achievable when testosterone is restored to physiologic levels.<\/p>\n<p class=\"wp-block-paragraph\">Still, the story is not finished. The 12-month <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">NCT07278362<\/a> study and the longer <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06733350\" target=\"_blank\" rel=\"noopener\">NCT06733350<\/a> trial will clarify risk, refine monitoring, and help define who benefits most. Until those results mature, the safest path is individualized care: careful selection, shared decision-making, and disciplined surveillance, with a low threshold to change course if the cancer\u2019s behavior changes.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-disclaimer\">\n<h3 class=\"wp-block-heading\">Disclaimer<\/h3>\n<p class=\"wp-block-paragraph\">This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about testosterone therapy and prostate cancer management should be made with a qualified healthcare professional familiar with your medical history.<\/p>\n<\/div>\n<div class=\"wp-block-group section-spacing\" id=\"h-sources\">\n<h3 class=\"wp-block-heading\">Sources<\/h3>\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06733350\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov: NCT06733350<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2024-09551\" target=\"_blank\" rel=\"noopener\">NCI\/Cancer.gov: Testosterone Replacement Therapy Trial (NCI-2024-09551)<\/a><\/li>\n<li><a href=\"https:\/\/www.renalandurologynews.com\/news\/prostate-cancer-active-surveillance-outcomes-unaffected-by-trt\/\" target=\"_blank\" rel=\"noopener\">Renal &amp; Urology News: Prostate Cancer Active Surveillance Outcomes Unaffected by TRT (Hussein et al., 2024)<\/a><\/li>\n<li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07278362\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov: NCT07278362<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39895152\/\" target=\"_blank\" rel=\"noopener\">PubMed: Testosterone Replacement Therapy in Men on Active Surveillance<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/testosterone-information\" target=\"_blank\" rel=\"noopener\">FDA Drug Safety Communication on Testosterone Products (updated 2025)<\/a><\/li>\n<li>TRAVERSE Trial cardiovascular outcomes data (FDA summary, 2024\u20132025)<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31928918\/\" target=\"_blank\" rel=\"noopener\">Corona et al., 2020. Testosterone Therapy: What We Have Learned From Trials. J Sex Med<\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TRT for Hypogonadal Men on Prostate Cancer Surveillance: What Trials Show Estimated reading time: 11 minutes Key takeaways Early evidence suggests TRT may be considered for hypogonadal men on active surveillance for low-risk, localized prostate cancer when monitoring is rigorous. Ongoing Phase IV trials (e.g., NCT07278362) are prospectively tracking disease progression, testosterone restoration, and symptom [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-228","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/comments?post=228"}],"version-history":[{"count":1,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/228\/revisions"}],"predecessor-version":[{"id":229,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/228\/revisions\/229"}],"wp:attachment":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/media?parent=228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/categories?post=228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/tags?post=228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}